Under: Weight Loss
Best Peptides for Hair Loss on GLP-1 Medications
Telogen effluvium (temporary hair shedding) is reported in 25-33% of GLP-1 users in some studies. It is caused by rapid weight loss triggering hair follicles into the resting phase, not by the medication directly.
Hair loss during GLP-1 therapy is a form of telogen effluvium — a temporary shedding triggered by rapid weight loss, caloric deficit, and metabolic stress rather than the drug itself. It typically begins 2-4 months after starting treatment and resolves within 6-12 months as the body adjusts. The STEP 1 trial reported hair loss in ~3% of participants, but real-world reports suggest higher rates (25-33%) when accounting for self-reported shedding. Adequate protein intake (1.0-1.2 g/kg/day), biotin supplementation, and slower dose escalation may help minimize hair loss. Peptides like GHK-Cu and thymosin beta-4 (TB-500) are being researched for their roles in hair follicle regeneration and wound healing, though clinical evidence for this specific use is limited.
Slowing the dose escalation schedule and ensuring adequate nutrition (especially protein and micronutrients) during weight loss may reduce the severity of telogen effluvium.
Peptides Studied for Hair Loss on GLP-1 Medications
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| Semaglutide Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030. | high | Hair loss reported in STEP trials and widely in real-world use. Caused by rapid weight loss, not the molecule itself. | |
| Liraglutide Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing. | medium | Less commonly reported than with semaglutide/tirzepatide, likely due to lower total weight loss. | |
| Tirzepatide Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose. | medium | SURMOUNT trials reported hair alopecia as an adverse event. Greater weight loss may correlate with higher incidence. |
Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.
Hair loss reported in STEP trials and widely in real-world use. Caused by rapid weight loss, not the molecule itself.
Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing.
Less commonly reported than with semaglutide/tirzepatide, likely due to lower total weight loss.
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
SURMOUNT trials reported hair alopecia as an adverse event. Greater weight loss may correlate with higher incidence.